These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30948845)

  • 1. Parkinson disease and growth factors - is GDNF good enough?
    Kirkeby A; Barker RA
    Nat Rev Neurol; 2019 Jun; 15(6):312-314. PubMed ID: 30948845
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
    Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
    J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
    Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
    Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research update on Parkinson's disease and other movement disorders: highlights from the Eighteenth Annual Symposium on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, October 3, 2004, Toronto, Ontario, Canada.
    Weiner WJ
    Rev Neurol Dis; 2005; 2(1):27-9. PubMed ID: 16400301
    [No Abstract]   [Full Text] [Related]  

  • 5. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
    Patel NK; Pavese N; Javed S; Hotton GR; Brooks DJ; Gill SS
    Neurology; 2013 Sep; 81(13):1176-8. PubMed ID: 23946313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuing trials of GDNF in Parkinson's disease.
    Barker RA
    Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740
    [No Abstract]   [Full Text] [Related]  

  • 7. GDNF in treatment of Parkinson's disease: response to editorial.
    Lang AE; Langston JW; Stoessl AJ; Brodsky M; Brooks DJ; Dhawan V; Elias WJ; Lozano AM; Moro E; Nutt JG; Stacy M; Turner D; Wooten GF
    Lancet Neurol; 2006 Mar; 5(3):200-2. PubMed ID: 16488373
    [No Abstract]   [Full Text] [Related]  

  • 8. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
    Yasuhara T; Shingo T; Date I
    Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDNF in treatment of Parkinson's disease: response to editorial.
    Penn RD; Dalvi A; Slevin J; Young B; Gash D; Gerhardt G; Hutchinson M
    Lancet Neurol; 2006 Mar; 5(3):202-3. PubMed ID: 16488374
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply: GDNF poses troubling questions for doctors, drug maker.
    Slevin JT; Gerhardt GA; Smith CD; Gash DM; Young AB
    Ann Neurol; 2006 Jun; 59(6):989-90. PubMed ID: 16718700
    [No Abstract]   [Full Text] [Related]  

  • 11. Neurotrophic factors as a therapeutic target for Parkinson's disease.
    Evans JR; Barker RA
    Expert Opin Ther Targets; 2008 Apr; 12(4):437-47. PubMed ID: 18348680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDNF in Parkinson disease: an object lesson in the tyranny of type II.
    Hutchinson M; Gurney S; Newson R
    J Neurosci Methods; 2007 Jul; 163(2):190-2. PubMed ID: 16876872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.
    Lang AE; Gill S; Patel NK; Lozano A; Nutt JG; Penn R; Brooks DJ; Hotton G; Moro E; Heywood P; Brodsky MA; Burchiel K; Kelly P; Dalvi A; Scott B; Stacy M; Turner D; Wooten VG; Elias WJ; Laws ER; Dhawan V; Stoessl AJ; Matcham J; Coffey RJ; Traub M
    Ann Neurol; 2006 Mar; 59(3):459-66. PubMed ID: 16429411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it time to abandon functional imaging in the study of neuroprotection?
    Morrish P
    Mov Disord; 2002 Mar; 17(2):229-32. PubMed ID: 11921106
    [No Abstract]   [Full Text] [Related]  

  • 15. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
    Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
    J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients.
    Ricci V; Pomponi M; Martinotti G; Bentivoglio A; Loria G; Bernardini S; Caltagirone C; Bria P; Angelucci F
    J Clin Psychopharmacol; 2010 Dec; 30(6):751-3. PubMed ID: 21057246
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.
    Herrán E; Requejo C; Ruiz-Ortega JA; Aristieta A; Igartua M; Bengoetxea H; Ugedo L; Pedraz JL; Lafuente JV; Hernández RM
    Int J Nanomedicine; 2014; 9():2677-87. PubMed ID: 24920904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease?
    Jankovic J
    Nat Rev Neurol; 2017 Nov; 13(11):643-644. PubMed ID: 28960185
    [No Abstract]   [Full Text] [Related]  

  • 19. Movement disorders: understanding clinical trials.
    Goetz CG
    Lancet Neurol; 2005 Jan; 4(1):5-6. PubMed ID: 15620847
    [No Abstract]   [Full Text] [Related]  

  • 20. GDNF and protection of adult central catecholaminergic neurons.
    Pascual A; Hidalgo-Figueroa M; Gómez-Díaz R; López-Barneo J
    J Mol Endocrinol; 2011 Jun; 46(3):R83-92. PubMed ID: 21357726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.